PSTV PE Ratio & Valuation,Is PSTV Overvalued

PSTV Relative Valuation

PSTV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PSTV is overvalued; if below, it's undervalued.

Historical Valuation

Plus Therapeutics Inc (PSTV) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.94 is considered Overvalued compared with the five-year average of -1.25. The fair price of Plus Therapeutics Inc (PSTV) is between 0.09 to 0.41 according to relative valuation methord. Compared to the current price of 0.68 USD , Plus Therapeutics Inc is Overvalued By 68.75%.

Relative Value

Fair Zone

0.09-0.41

Current Price：0.68

68.75%

Overvalued

-4.67

-5.70

EV/EBITDA

Plus Therapeutics Inc. (PSTV) has a current EV/EBITDA of -5.70. The 5-year average EV/EBITDA is -0.88. The thresholds are as follows: Strongly Undervalued below -3.27, Undervalued between -3.27 and -2.07, Fairly Valued between 0.32 and -2.07, Overvalued between 0.32 and 1.51, and Strongly Overvalued above 1.51. The current Forward EV/EBITDA of -5.70 falls within the Strongly Undervalued range.

-4.42

EV/EBIT

Plus Therapeutics Inc. (PSTV) has a current EV/EBIT of -4.42. The 5-year average EV/EBIT is -0.68. The thresholds are as follows: Strongly Undervalued below -2.62, Undervalued between -2.62 and -1.65, Fairly Valued between 0.29 and -1.65, Overvalued between 0.29 and 1.26, and Strongly Overvalued above 1.26. The current Forward EV/EBIT of -4.42 falls within the Strongly Undervalued range.

13.94

Plus Therapeutics Inc. (PSTV) has a current PS of 13.94. The 5-year average PS is 3.22. The thresholds are as follows: Strongly Undervalued below -9.77, Undervalued between -9.77 and -3.27, Fairly Valued between 9.71 and -3.27, Overvalued between 9.71 and 16.20, and Strongly Overvalued above 16.20. The current Forward PS of 13.94 falls within the Overvalued range.

-5.73

P/OCF

Plus Therapeutics Inc. (PSTV) has a current P/OCF of -5.73. The 5-year average P/OCF is -1.55. The thresholds are as follows: Strongly Undervalued below -4.60, Undervalued between -4.60 and -3.07, Fairly Valued between -0.02 and -3.07, Overvalued between -0.02 and 1.50, and Strongly Overvalued above 1.50. The current Forward P/OCF of -5.73 falls within the Strongly Undervalued range.

0.00

P/FCF

Plus Therapeutics Inc. (PSTV) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.40. The thresholds are as follows: Strongly Undervalued below -1.71, Undervalued between -1.71 and -1.06, Fairly Valued between 0.25 and -1.06, Overvalued between 0.25 and 0.91, and Strongly Overvalued above 0.91. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Plus Therapeutics Inc (PSTV) has a current Price-to-Book (P/B) ratio of 17.62. Compared to its 3-year average P/B ratio of 2.17 , the current P/B ratio is approximately 711.30% higher. Relative to its 5-year average P/B ratio of 2.19, the current P/B ratio is about 705.62% higher. Plus Therapeutics Inc (PSTV) has a Forward Free Cash Flow (FCF) yield of approximately -16.79%. Compared to its 3-year average FCF yield of -142.77%, the current FCF yield is approximately -88.24% lower. Relative to its 5-year average FCF yield of -110.25% , the current FCF yield is about -84.77% lower.

17.62

P/B

Median3y

2.17

Median5y

2.19

-16.79

FCF Yield

Median3y

-142.77

Median5y

-110.25

Competitors Valuation Multiple

The average P/S ratio for PSTV's competitors is 5.16, providing a benchmark for relative valuation. Plus Therapeutics Inc Corp (PSTV) exhibits a P/S ratio of 13.94, which is 170.26% above the industry average. Given its robust revenue growth of -4.05%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PSTV decreased by 40.54% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -197.39 to -316.61.

The secondary factor is the Revenue Growth, contributed -4.05%to the performance.

Overall, the performance of PSTV in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-4.05%

1.46M → 1.40M

Revenue Growth

60.40%

-197.39 → -316.61

Margin Expansion

-96.89%

-47.71 → -1.48

P/E Change

-40.54%

1.15 → 0.68

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Plus Therapeutics Inc (PSTV) currently overvalued or undervalued?

What is Plus Therapeutics Inc (PSTV) fair value?

PSTV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Plus Therapeutics Inc (PSTV) is between 0.09 to 0.41 according to relative valuation methord.

How does PSTV's valuation metrics compare to the industry average?

What is the current P/B ratio for Plus Therapeutics Inc (PSTV) as of Dec 15 2025?

As of Dec 15 2025, Plus Therapeutics Inc (PSTV) has a P/B ratio of 17.62. This indicates that the market values PSTV at 17.62 times its book value.

What is the current FCF Yield for Plus Therapeutics Inc (PSTV) as of Dec 15 2025?

As of Dec 15 2025, Plus Therapeutics Inc (PSTV) has a FCF Yield of -16.79%. This means that for every dollar of Plus Therapeutics Inc’s market capitalization, the company generates -16.79 cents in free cash flow.

What is the current Forward P/E ratio for Plus Therapeutics Inc (PSTV) as of Dec 15 2025?

As of Dec 15 2025, Plus Therapeutics Inc (PSTV) has a Forward P/E ratio of -4.67. This means the market is willing to pay $-4.67 for every dollar of Plus Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Plus Therapeutics Inc (PSTV) as of Dec 15 2025?

As of Dec 15 2025, Plus Therapeutics Inc (PSTV) has a Forward P/S ratio of 13.94. This means the market is valuing PSTV at $13.94 for every dollar of expected revenue over the next 12 months.

PSTV Valuation